Patent Filed For Monoclonal Antibody Against COVID-19 Antigens

Pennsylvania-based Halberd Corporation reported its research team developed a 2nd monoclonal antibody against Covid-19 SARS 2 disease antigens paving the way for the development of a potentially more effective nasal spray. Dr. Mitchell S. Felder, a Halberd consultant, stated on November 5, 2020, a provisional patent application for a nasal spray utilizing the antibodies generated to date against the Covid-19 virus spike protein, along with antibodies against ACE2 receptors, and Neuropilin-1 has been filed.

This approach should eliminate or reduce Covid-19 viral load, which concomitantly greatly reduces clinical manifestations, with what should be a statistically significant reduction in Covid-19 morbidity and mortality.